Sector: MedicalAllos Therapeutics, Inc. (NASDAQ: ALTH)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 253 |
Technical : | 165 |
Performance : | 265 |
Overall: | 275 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 248 |
Technical : | 300 |
Performance : | 293 |
Overall: | 303 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 246 |
Technical : | 302 |
Performance : | 288 |
Overall: | 304 |
Number of Stocks: | 306 |
Headlines
- Allos Therapeutics Announces New Data on FOLOTYN(TM) to be Presented at the American Society of Hematology Meeting
Nov 11, 2009 08:00 AM | ALTH
- Allos Therapeutics to Present at Upcoming Conferences in November
Nov 10, 2009 09:51 AM | ALTH
- NCCN Receives Research Grant to Evaluate Pralatrexate in Solid Tumors and Hematologic Malignancies
Nov 10, 2009 09:13 AM | ALTH
- Allos Therapeutics Reports Third Quarter 2009 Financial Results
Nov 03, 2009 04:01 PM | ALTH
- Allos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009
Oct 26, 2009 08:00 AM | ALTH
- NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate
Oct 15, 2009 09:03 AM | ALTH
- Allos Therapeutics Announces Closing of Public Offering
Oct 13, 2009 04:05 PM | ALTH, C, RY
- Allos Therapeutics Announces Proposed Public Offering of Common Stock
Oct 05, 2009 04:01 PM | ALTH, C
- Allos Therapeutics Announces U.S. Availability of FOLOTYN(TM) (pralatrexate injection) for Relapsed or Refractory Peripheral T-Cell Lymphoma
Oct 05, 2009 07:01 AM | ALTH
- JMP Securities Healthcare Conference to Be Held in New York
Sep 29, 2009 05:30 PM | ACAD, ALNY, ALTH, ALXA, ANDS, ATHN
- Allos Therapeutics Announces Pricing of Public Offering of Common Stock
Oct 07, 2009 06:52 AM | ALTH
- Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Aug 10, 2009 10:26 AM | ALTH
- Allos Therapeutics Reports Second Quarter 2009 Financial Results
Aug 04, 2009 04:02 PM | ALTH
- Allos Therapeutics Launches Peripheral T-Cell Lymphoma Website
Jul 23, 2009 10:07 AM | ALTH
- Allos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009
Jul 22, 2009 08:13 AM | ALTH
- Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell Lung Cancer
Jul 07, 2009 08:14 AM | ALTH
- InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren Resources
Jun 29, 2009 08:40 AM | ALTH, AMAT, BGCP, MDRX, VVTV, WRES
- Allos Therapeutics to Present at the 8th Annual Needham Life Sciences Conference
Jun 03, 2009 08:02 AM | ALTH
- Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting
May 30, 2009 08:01 AM | ALTH
- Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
May 26, 2009 08:09 AM | ALTH
- Form 4 ALLOS THERAPEUTICS INC For: Sep 30 Filed by: CAGNONI PABLO J (10K)
Oct 02, 2009 07:33 PM
- Form 4 ALLOS THERAPEUTICS INC For: Aug 10 Filed by: BERNS PAUL L (10K)
Aug 12, 2009 07:40 PM
- Form 4 ALLOS THERAPEUTICS INC For: Aug 10 Filed by: CARUSO JAMES V (10K)
Aug 12, 2009 07:34 PM
- Form 4 ALLOS THERAPEUTICS INC For: Aug 05 Filed by: BERNS PAUL L (10K)
Aug 07, 2009 07:35 PM
- Form 4 ALLOS THERAPEUTICS INC For: Aug 03 Filed by: CARUSO JAMES V (10K)
Aug 05, 2009 07:38 PM
- Form 4 Graboyes Marc H For: Aug 03 (10K)
Aug 05, 2009 07:35 PM
- Form 4 ALLOS THERAPEUTICS INC For: Jun 30 Filed by: BENNETT BRUCE K JR (10K)
Jul 01, 2009 06:41 PM
- Form 4 STOUT DAVID M For: Jun 23 (10K)
Jun 23, 2009 08:47 PM
- Form 4 ALLOS THERAPEUTICS INC For: Jun 23 Filed by: CASEY MICHAEL D (10K)
Jun 23, 2009 08:46 PM
- Form 4 ALLOS THERAPEUTICS INC For: Jun 23 Filed by: HEN STEWART (10K)
Jun 23, 2009 08:46 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ALTH
|
Compare to S&P
|
| YTD |
-2.61 %
|
-19.56 %
|
| 4 Weeks |
-13.87 %
|
-14.33 %
|
| 12 Weeks |
-24.56 %
|
-29.20 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -10.53 %
|
|
EPS Growth in Last Year: -31.25 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
